Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.
“tests like these assure patients get the best cancer care, as clinicians use these results to determine the best treatment strategies based on the patients tumor profile - It's really that simple.”
Benjamin Kipp, Ph.D., chair of the Division of Laboratory Genetics and Genomics
Our difference
The latest
PACE / State of FL - Register now - May 21, 2025: - This webinar will explore the role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer. Advantages of cytology samples, challenges in specimen adequacy, and how advancements in next-generation sequencing (NGS) have led to improved utilization of cytology samples will be discussed. This discovery has led to enhancing diagnostic accuracy, reducing the need for repeat biopsies, and accelerating personalized cancer treatment, all of which will be highlighted during the webinar.
This week’s Research Roundup highlights the comparison of risk stratification models to predict recurrence and survival in pleuropulmonary solitary fibrous tumor.
This week’s Research Roundup highlights the association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer.
According to Mayo Clinic research published in JAMA, six genes contain mutations that may be passed down in families, substantially increasing a person’s risk for pancreatic cancer.
This week’s Research Roundup highlights the detection of gastric cancer with novel methylated DNA markers: discovery, tissue validation, and pilot testing in plasma.
This week’s Research Roundup highlights the development and validation of a prostate cancer genomic signature that predicts early androgen deprivation therapy (ADT) treatment response following radical prostatectomy.
Melanoma, the skin cancer often associated with sun exposure, is on the rise and has no reliable cure. Mayo Clinic is at the forefront of these efforts. The Center for Individualized Medicine is unraveling the complex behavior of melanoma at the molecular level—to allow for treatment that better targets an individual's disease.
This week’s Research Roundup highlights a model for predicting breast cancer risk in women with atypical hyperplasia.
This week’s Research Roundup highlights genetic evidence for early peritoneal spreading in pelvic high-grade serous cancer.
This week’s Research Roundup highlights the blast phase myeloproliferative neoplasm with a Mayo-AGIMM study of 410 patients from two separate cohorts.
This week’s Research Roundup highlights the genomic analysis using regularized regression in high-grade serous ovarian cancer.